NCT04047472View on ClinicalTrials.gov

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration

PHASE3CompletedINTERVENTIONAL
Enrollment

397

Participants

Timeline

Start Date

November 29, 2019

Primary Completion Date

February 28, 2024

Study Completion Date

February 28, 2024

Conditions
Neovascular Age-Related Macular Degeneration
Interventions
DRUG

Brolucizumab 6mg

Intravitreal injection

DRUG

Aflibercept 2 mg

Intravitreal injection

Trial Locations (30)

100034

Novartis Investigative Site, Beijing

100044

Novartis Investigative Site, Beijing

100050

Novartis Investigative Site, Beijing

100191

Novartis Investigative Site, Beijing

100730

Novartis Investigative Site, Beijing

110000

Novartis Investigative Site, Shenyang

130041

Novartis Investigative Site, Changchun

150001

Novartis Investigative Site, Harbin

200001

Novartis Investigative Site, Shanghai

200031

Novartis Investigative Site, Shanghai

200080

Novartis Investigative Site, Shanghai

200092

Novartis Investigative Site, Shanghai

210000

Novartis Investigative Site, Nanjing

210029

Novartis Investigative Site, Nanjing

214299

Novartis Investigative Site, Yixing

226000

Novartis Investigative Site, Nantong

250004

Novartis Investigative Site, Jinan

250012

Novartis Investigative Site, Jinan

300020

Novartis Investigative Site, Tianjin

310003

Novartis Investigative Site, Hangzhou

310014

Novartis Investigative Site, Hangzhou

400038

Novartis Investigative Site, Chongqing

400042

Novartis Investigative Site, Chongqing

410015

Novartis Investigative Site, Guangzhou

430060

Novartis Investigative Site, Wuhan

430070

Novartis Investigative Site, Wuhan

510060

Novartis Investigative Site, Guangzhou

515041

Novartis Investigative Site, Shantou

710004

Novartis Investigative Site, Xi'an

030002

Novartis Investigative Site, Taiyuan

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY